BACKGROUND: The clinical relevance of polymerase chain reaction (PCR)-based techniques for detection of disseminated tumour cells (DTCs) in the bone marrow of bladder cancer (BCa) patients is still under debate, as data on long-term follow-up analysis have not yet been published. OBJECTIVE: The aim of the present prospective study was to assess the prognostic significance of DTCs detected by cytokeratin-20 (CK20) reverse-transcriptase PCR in bone marrow from BCa patients undergoing radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Bone marrow samples from 51 BCa patients with high-risk non-muscle-invasive or muscle-invasive urothelial carcinoma were drawn from the anterior iliac crest prior to RC. CK20-positive cells in bone marrow were detected by qualitative RT-PCR. MEASUREMENTS: BCa patients with CK20 status were analysed with respect to the end points tumour progression and cancer death. A multivariate Cox regression analysis was performed to determine independent prognostic factors for progression-free survival (PFS), tumour-specific survival (TSS), and overall survival (OS). RESULTS AND LIMITATIONS: CK20-positive cells were detected in 16 of 51 (31.4%) BCa patients of all stages. BCa patients with CK20-negative status displayed a 7-yr PFS rate of 64% versus 35.2% for CK20-positive patients (p=0.007). TSS was significantly shorter in the CK20-positive group, with a 7-yr survival rate of 46.9% compared to CK20-negative patients with 70.2% (p=0.012). The 7-yr OS rate of 37.5% for CK20-positive patients was significantly <65.7% in the CK20-negative group (p=0.006). A subgroup analysis of lymph node-negative patients (pN0) discriminated by CK20 status revealed significant differences in PFS, TSS, and OS. In a multivariate analysis, CK20-status provides independent prognostic information with respect to all three survival end points. CONCLUSIONS: BCa patients with positive CK20 status in bone marrow represent a high-risk subgroup reflected by an unfavourable outcome in the long-term analysis.
BACKGROUND: The clinical relevance of polymerase chain reaction (PCR)-based techniques for detection of disseminated tumour cells (DTCs) in the bone marrow of bladder cancer (BCa) patients is still under debate, as data on long-term follow-up analysis have not yet been published. OBJECTIVE: The aim of the present prospective study was to assess the prognostic significance of DTCs detected by cytokeratin-20 (CK20) reverse-transcriptase PCR in bone marrow from BCa patients undergoing radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Bone marrow samples from 51 BCa patients with high-risk non-muscle-invasive or muscle-invasive urothelial carcinoma were drawn from the anterior iliac crest prior to RC. CK20-positive cells in bone marrow were detected by qualitative RT-PCR. MEASUREMENTS: BCa patients with CK20 status were analysed with respect to the end points tumour progression and cancer death. A multivariate Cox regression analysis was performed to determine independent prognostic factors for progression-free survival (PFS), tumour-specific survival (TSS), and overall survival (OS). RESULTS AND LIMITATIONS: CK20-positive cells were detected in 16 of 51 (31.4%) BCa patients of all stages. BCa patients with CK20-negative status displayed a 7-yr PFS rate of 64% versus 35.2% for CK20-positive patients (p=0.007). TSS was significantly shorter in the CK20-positive group, with a 7-yr survival rate of 46.9% compared to CK20-negative patients with 70.2% (p=0.012). The 7-yr OS rate of 37.5% for CK20-positive patients was significantly <65.7% in the CK20-negative group (p=0.006). A subgroup analysis of lymph node-negative patients (pN0) discriminated by CK20 status revealed significant differences in PFS, TSS, and OS. In a multivariate analysis, CK20-status provides independent prognostic information with respect to all three survival end points. CONCLUSIONS: BCa patients with positive CK20 status in bone marrow represent a high-risk subgroup reflected by an unfavourable outcome in the long-term analysis.
Authors: Johannes Breyer; Ralph M Wirtz; Wolfgang Otto; Philipp Erben; Maximilian C Kriegmair; Robert Stoehr; Markus Eckstein; Sebastian Eidt; Stefan Denzinger; Maximilian Burger; Arndt Hartmann Journal: Virchows Arch Date: 2017-01-10 Impact factor: 4.064
Authors: B Keck; A S Merseburger; R Stöhr; S Füssel; M J Hoffmann; S Schmid; P Olbert; A Hartmann; R Nawroth Journal: Urologe A Date: 2013-03 Impact factor: 0.639
Authors: David J DeGraff; Peter E Clark; Justin M Cates; Hironobu Yamashita; Victoria L Robinson; Xiuping Yu; Mark E Smolkin; Sam S Chang; Michael S Cookson; Mary K Herrick; Shahrokh F Shariat; Gary D Steinberg; Henry F Frierson; Xue-Ru Wu; Dan Theodorescu; Robert J Matusik Journal: PLoS One Date: 2012-05-10 Impact factor: 3.240
Authors: Markus Eckstein; Ralph Markus Wirtz; Matthias Gross-Weege; Johannes Breyer; Wolfgang Otto; Robert Stoehr; Danijel Sikic; Bastian Keck; Sebastian Eidt; Maximilian Burger; Christian Bolenz; Katja Nitschke; Stefan Porubsky; Arndt Hartmann; Philipp Erben Journal: Int J Mol Sci Date: 2018-10-30 Impact factor: 5.923